\-\ Texto\\:\\ \ \(0\)\
\-\ general\\:\\ \\ alert\\,\\ active\\,\\ in\\ nad\ \(0\)\
\-\ vitals\\:\\ \\ pulse\\ 117\\,\\ respirations\\ 24\\,\\ bp\\ 111\\/69\\,\\ temp\\.\\ 37\\.3\ \(0\)\
\-\ heent\\:\\ \\ eyes\\ are\\ normal\\ without\\ lisch\\ nodules\ \(0\)\
\-\ skin\\:\\ \\ multiple\\ cafe\\-au\\-lait\\ spots\\,\\ one\\ large\\ spot\\ over\\ back\\ and\\ thigh\\,\\ a\\ total\\ of\\ 10\\-15\\ spots\\ \\>1cm\ \(0\)\
\-\ ms\\:\\ \\ back\\ is\\ straight\\ without\\ evidence\\ of\\ scoliosis\ \(0\)\
\-\ no\\ treatment\\,\\ a\\ follow\\-up\\ mri\\ will\\ be\\ obtained\\ to\\ ensure\\ no\\ growth\\.\\ \\ however\\,\\ the\\ national\\ neurofibromatosis\\ foundation\\ does\\ not\\ recommend\\ neuroimaging\\ for\\ screening\\ in\\ asymptomatic\\ children\\ with\\ nf1\\.\ \(0\)\
\-\ yearly\\ ophthamologic\\ exam\\ to\\ evaluate\\ for\\ lisch\\ nodules\\ and\\ optic\\ gliomas\\.\ \(0\)\
\-\ yearly\\ bp\\ check\\ since\\ hypertension\\ is\\ frequent\\ in\\ patients\\ with\\ nf1\\ and\\ can\\ occur\\ at\\ any\\ age\\.\ \(0\)\
\-\ regular\\ growth\\ assessments\\ since\\ most\\ nf1\\ patients\\ have\\ short\\ stature\\ and\\ check\\ for\\ scoliosis\\ which\\ occurs\\ in\\ 10\\-25\\%\\ of\\ affected\\ individuals\\.\ \(0\)\
\-\ developmental\\ evaluations\\.\ \(0\)\
\-\ increase\\ signal\\ in\\ globus\\ pallidus\\ bilaterally\\ which\\ does\\ not\\ enhance\\.\\ \\ there\\ are\\ also\\ area\\ of\\ abnormal\\ signal\\ in\\ the\\ cerebellum\\.\ \(0\)\
\-\ hamartoma\\ 2nd\\ to\\ nf\\-1\ \(0\)\
\-\ hamartoma\ \(55\)\
\-\ low\\ grade\\ tumor\ \(0\)\
\-\ heterotopias\ \(3\)\
\-\ myelination\\ disorder\ \(0\)\
\-\ gliosis\ \(20\)\
\-\ the\\ patient\\ is\\ a\\ 7\\ y\\/o\\ caucasian\\ male\\ who\\ presented\\ for\\ evaluation\\ after\\ confirmation\\ of\\ a\\ positive\\ family\\ history\\ of\\ neurofibromatosis\\ type\\ 1\\ \\(mother\\,\\ older\\ brother\\,\\ and\\ maternal\\ grandmother\\)\\.\\ \\ he\\ also\\ presented\\ with\\ cafe\\-au\\-lait\\ spots\\ shortly\\ after\\ birth\\.\\ \\ developmentally\\,\\ the\\ patient\\ was\\ in\\ the\\ 25\\%\\ for\\ height\\ and\\ weight\\ and\\ 70\\%\\ for\\ head\\ circumference\\ and\\ had\\ some\\ speech\\ problems\\.\\ \\ the\\ patient\\ was\\ otherwise\\ healthy\\.\\ \\ last\\ year\\ his\\ mother\\ was\\ diagnosed\\ with\\ glioblastoma\\ multiforme\\.\ \(0\)\
\-\ a\\ hamartoma\\ is\\ a\\ lesion\\ made\\ of\\ normal\\ cells\\ in\\ an\\ abnormal\\ location\\.\\ \\ they\\ are\\ one\\ of\\ many\\ brain\\ lesions\\ seen\\ in\\ patients\\ with\\ neurofibromatosis\\ type\\ 1\\.\\ \\ the\\ important\\ aspect\\ is\\ to\\ differentiate\\ a\\ hamartoma\\ from\\ an\\ astrocytoma\\,\\ glioma\\,\\ or\\ other\\ cns\\ tumor\\.\\ \\ a\\ hamartoma\\ should\\ not\\ enhance\\ since\\ enhancement\\ usually\\ indicates\\ an\\ actively\\ growing\\ tumor\\.\\ \\ also\\,\\ there\\ should\\ be\\ very\\ little\\ or\\ no\\ growth\\.\\ \\ clinically\\,\\ the\\ patient\\ should\\ be\\ asymptomatic\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hamartoma\\:\\ 0\\.28584642565427554\ \(0\)\
\-\ spots\\:\\ 0\\.211682046895621\ \(0\)\
\-\ nf1\\:\\ 0\\.211682046895621\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.17290809267640048\ \(0\)\
\-\ lisch\\:\\ 0\\.16722380939979625\ \(0\)\
\-\ growth\\:\\ 0\\.14377501561524852\ \(0\)\
\-\ yearly\\:\\ 0\\.13703216376100325\ \(0\)\
\-\ check\\:\\ 0\\.1314027641315484\ \(0\)\
\-\ in\\:\\ 0\\.13012715653199144\ \(0\)\
\-\ scoliosis\\:\\ 0\\.1287697303486027\ \(0\)\
\-\ since\\:\\ 0\\.1263034481327675\ \(0\)\
\-\ should\\:\\ 0\\.11377148781347789\ \(0\)\
\-\ for\\:\\ 0\\.10569584099137164\ \(0\)\
\-\ enhance\\:\\ 0\\.10405115755642295\ \(0\)\
\-\ mother\\:\\ 0\\.09932125174129919\ \(0\)\
\-\ patients\\:\\ 0\\.09808841414487747\ \(0\)\
\-\ and\\:\\ 0\\.09607964168833047\ \(0\)\
\-\ bp\\:\\ 0\\.09431357463201204\ \(0\)\
\-\ ophthamologic\\:\\ 0\\.09294783892347913\ \(0\)\
\-\ the\\:\\ 0\\.09277767144317202\ \(0\)\
\-\ nodules\\:\\ 0\\.09236102879805161\ \(0\)\
\-\ tumor\\:\\ 0\\.09120167790399726\ \(0\)\
\-\ of\\:\\ 0\\.09099189266552264\ \(0\)\
\-\ 25\\:\\ 0\\.08234850604946425\ \(0\)\
\-\ also\\:\\ 0\\.08201509949215684\ \(0\)\
\-\ foundation\\:\\ 0\\.08175426061100974\ \(0\)\
\-\ myelination\\:\\ 0\\.08175426061100974\ \(0\)\
\-\ does\\:\\ 0\\.08036033350968821\ \(0\)\
\-\ assessments\\:\\ 0\\.08018364491303798\ \(0\)\
\-\ is\\:\\ 0\\.07958390270249117\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0791350773481224\ \(0\)\
\-\ heterotopias\\:\\ 0\\.07882311571094087\ \(0\)\
\-\ grandmother\\:\\ 0\\.07882311571094087\ \(0\)\
\-\ developmentally\\:\\ 0\\.07882311571094087\ \(0\)\
\-\ type\\:\\ 0\\.07797933284682063\ \(0\)\
\-\ back\\:\\ 0\\.07752479352274672\ \(0\)\
\-\ actively\\:\\ 0\\.076549543093629\ \(0\)\
\-\ patient\\:\\ 0\\.07561513583228875\ \(0\)\
\-\ pallidus\\:\\ 0\\.07557844348677074\ \(0\)\
\-\ 117\\:\\ 0\\.0746918990047406\ \(0\)\
\-\ evaluations\\:\\ 0\\.0746918990047406\ \(0\)\
\-\ brother\\:\\ 0\\.07241832638742873\ \(0\)\
\-\ national\\:\\ 0\\.07114305989265014\ \(0\)\
\-\ globus\\:\\ 0\\.07114305989265014\ \(0\)\
\-\ be\\:\\ 0\\.07073187543635286\ \(0\)\
\-\ neuroimaging\\:\\ 0\\.07056068229854033\ \(0\)\
\-\ stature\\:\\ 0\\.07056068229854033\ \(0\)\
\-\ gliosis\\:\\ 0\\.07056068229854033\ \(0\)\
\-\ abnormal\\:\\ 0\\.06983641689217945\ \(0\)\
\-\ not\\:\\ 0\\.06883414771213392\ \(0\)\
\-\ presented\\:\\ 0\\.06778553652414036\ \(0\)\
\-\ recommend\\:\\ 0\\.06762953739847148\ \(0\)\
\-\ gliomas\\:\\ 0\\.067213608870048\ \(0\)\
\-\ an\\:\\ 0\\.06667561568860148\ \(0\)\
\-\ one\\:\\ 0\\.06655379184943767\ \(0\)\
\-\ are\\:\\ 0\\.06616261991391247\ \(0\)\
\-\ circumference\\:\\ 0\\.06605892170049972\ \(0\)\
\-\ signal\\:\\ 0\\.06589407713832522\ \(0\)\
\-\ respirations\\:\\ 0\\.0657013820657742\ \(0\)\
\-\ maternal\\:\\ 0\\.06349832069227121\ \(0\)\
\-\ confirmation\\:\\ 0\\.06217323094874331\ \(0\)\
\-\ 1cm\\:\\ 0\\.0616879566606888\ \(0\)\
\-\ without\\:\\ 0\\.06131309131779087\ \(0\)\
\-\ differentiate\\:\\ 0\\.06122474807495933\ \(0\)\
\-\ indicates\\:\\ 0\\.06122474807495933\ \(0\)\
\-\ individuals\\:\\ 0\\.060781685485049586\ \(0\)\
\-\ was\\:\\ 0\\.06076704018235594\ \(0\)\
\-\ ensure\\:\\ 0\\.060567175792202346\ \(0\)\
\-\ multiforme\\:\\ 0\\.060567175792202346\ \(0\)\
\-\ speech\\:\\ 0\\.05994948158018074\ \(0\)\
\-\ shortly\\:\\ 0\\.05955755502767751\ \(0\)\
\-\ to\\:\\ 0\\.05812036008395804\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.057959513111082696\ \(0\)\
\-\ nad\\:\\ 0\\.057796488288099176\ \(0\)\
\-\ temp\\:\\ 0\\.05763603089213349\ \(0\)\
\-\ thigh\\:\\ 0\\.05716928513085511\ \(0\)\
\-\ little\\:\\ 0\\.05716928513085511\ \(0\)\
\-\ growing\\:\\ 0\\.057018336680111886\ \(0\)\
\-\ with\\:\\ 0\\.05690391268731758\ \(0\)\
\-\ spot\\:\\ 0\\.05672298747691872\ \(0\)\
\-\ no\\:\\ 0\\.056700684799531796\ \(0\)\
\-\ eyes\\:\\ 0\\.05643595908600208\ \(0\)\
\-\ ms\\:\\ 0\\.05643595908600208\ \(0\)\
\-\ after\\:\\ 0\\.05639072195182365\ \(0\)\
\-\ straight\\:\\ 0\\.05615679548441175\ \(0\)\
\-\ height\\:\\ 0\\.05575188787006047\ \(0\)\
\-\ pulse\\:\\ 0\\.05486534338803032\ \(0\)\
\-\ cns\\:\\ 0\\.05427622937445772\ \(0\)\
\-\ older\\:\\ 0\\.05393844703517328\ \(0\)\
\-\ alert\\:\\ 0\\.053504814185933225\ \(0\)\
\-\ cerebellum\\:\\ 0\\.053399229468363334\ \(0\)\
\-\ frequent\\:\\ 0\\.053294727690058566\ \(0\)\
\-\ 2nd\\:\\ 0\\.05319128686183195\ \(0\)\
\-\ which\\:\\ 0\\.05285622730322698\ \(0\)\
\-\ heent\\:\\ 0\\.051934198487961464\ \(0\)\
\-\ birth\\:\\ 0\\.051934198487961464\ \(0\)\
\-\ caucasian\\:\\ 0\\.05166487441786141\ \(0\)\
\-\ vitals\\:\\ 0\\.05131650427593986\ \(0\)\
\-\ problems\\:\\ 0\\.050415699701916006\ \(0\)\
\-\ developmental\\:\\ 0\\.050260141961763094\ \(0\)\
\-\ regular\\:\\ 0\\.050183244735879706\ \(0\)\
\-\ optic\\:\\ 0\\.05003116976248994\ \(0\)\
\-\ short\\:\\ 0\\.04995597507384276\ \(0\)\
\-\ glioma\\:\\ 0\\.04937359747973295\ \(0\)\
\-\ healthy\\:\\ 0\\.04930308623592407\ \(0\)\
\-\ important\\:\\ 0\\.04923305960930315\ \(0\)\
\-\ disorder\\:\\ 0\\.049163510983858294\ \(0\)\
\-\ clinically\\:\\ 0\\.04830009666855249\ \(0\)\
\-\ 70\\:\\ 0\\.04798656934445123\ \(0\)\
\-\ affected\\:\\ 0\\.04780298178176119\ \(0\)\
\-\ total\\:\\ 0\\.0476226437276512\ \(0\)\
\-\ children\\:\\ 0\\.0476226437276512\ \(0\)\
\-\ normal\\:\\ 0\\.04746067952679007\ \(0\)\
\-\ last\\:\\ 0\\.047271269802079845\ \(0\)\
\-\ screening\\:\\ 0\\.04721386776818859\ \(0\)\
\-\ general\\:\\ 0\\.046656962272511336\ \(0\)\
\-\ increase\\:\\ 0\\.046656962272511336\ \(0\)\
\-\ there\\:\\ 0\\.04625218521795145\ \(0\)\
\-\ occurs\\:\\ 0\\.045824758367642486\ \(0\)\
\-\ many\\:\\ 0\\.045824758367642486\ \(0\)\
\-\ family\\:\\ 0\\.04572535432000208\ \(0\)\
\-\ evaluate\\:\\ 0\\.04519531910064154\ \(0\)\
\-\ made\\:\\ 0\\.044826452245109207\ \(0\)\
\-\ cells\\:\\ 0\\.044781268871433695\ \(0\)\
\-\ hypertension\\:\\ 0\\.04447047423718824\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.043875956960877\ \(0\)\
\-\ skin\\:\\ 0\\.043236447703862486\ \(0\)\
\-\ active\\:\\ 0\\.04315925919782738\ \(0\)\
\-\ occur\\:\\ 0\\.04274486872270388\ \(0\)\
\-\ diagnosed\\:\\ 0\\.042101149377589166\ \(0\)\
\-\ grade\\:\\ 0\\.04179392507507234\ \(0\)\
\-\ very\\:\\ 0\\.04169354166144221\ \(0\)\
\-\ they\\:\\ 0\\.04152840297246226\ \(0\)\
\-\ otherwise\\:\\ 0\\.04143058941421275\ \(0\)\
\-\ 24\\:\\ 0\\.04120594460258856\ \(0\)\
\-\ obtained\\:\\ 0\\.04111116406733241\ \(0\)\
\-\ weight\\:\\ 0\\.04053053367961741\ \(0\)\
\-\ location\\:\\ 0\\.04047129610539201\ \(0\)\
\-\ or\\:\\ 0\\.04043839445252616\ \(0\)\
\-\ bilaterally\\:\\ 0\\.03876239676137336\ \(0\)\
\-\ positive\\:\\ 0\\.03829863324336706\ \(0\)\
\-\ area\\:\\ 0\\.037651505691474844\ \(0\)\
\-\ any\\:\\ 0\\.03756232495524195\ \(0\)\
\-\ aspect\\:\\ 0\\.03749594795132194\ \(0\)\
\-\ will\\:\\ 0\\.03740811263091911\ \(0\)\
\-\ usually\\:\\ 0\\.036589207557691614\ \(0\)\
\-\ some\\:\\ 0\\.0365690515984649\ \(0\)\
\-\ age\\:\\ 0\\.03648882414406148\ \(0\)\
\-\ brain\\:\\ 0\\.036232363667721486\ \(0\)\
\-\ evaluation\\:\\ 0\\.03544533464785269\ \(0\)\
\-\ his\\:\\ 0\\.035248874267194696\ \(0\)\
\-\ head\\:\\ 0\\.03466453142395809\ \(0\)\
\-\ he\\:\\ 0\\.03441701721034775\ \(0\)\
\-\ however\\:\\ 0\\.03440072810365474\ \(0\)\
\-\ enhancement\\:\\ 0\\.0334533303605035\ \(0\)\
\-\ lesions\\:\\ 0\\.0333794443654637\ \(0\)\
\-\ low\\:\\ 0\\.033350039340533696\ \(0\)\
\-\ evidence\\:\\ 0\\.032989462644610376\ \(0\)\
\-\ who\\:\\ 0\\.03287672197491704\ \(0\)\
\-\ over\\:\\ 0\\.03231772936712584\ \(0\)\
\-\ can\\:\\ 0\\.030499963348972817\ \(0\)\
\-\ most\\:\\ 0\\.030247833018922525\ \(0\)\
\-\ other\\:\\ 0\\.030183073262351725\ \(0\)\
\-\ mri\\:\\ 0\\.029834070253939308\ \(0\)\
\-\ exam\\:\\ 0\\.029258048222979224\ \(0\)\
\-\ large\\:\\ 0\\.02912141430096214\ \(0\)\
\-\ have\\:\\ 0\\.029034535985289125\ \(0\)\
\-\ had\\:\\ 0\\.028957927849450067\ \(0\)\
\-\ multiple\\:\\ 0\\.02842815641525908\ \(0\)\
\-\ lesion\\:\\ 0\\.027864412484769247\ \(0\)\
\-\ treatment\\:\\ 0\\.02768602900767398\ \(0\)\
\-\ seen\\:\\ 0\\.02736280993349852\ \(0\)\
\-\ male\\:\\ 0\\.025877623425701893\ \(0\)\
\-\ from\\:\\ 0\\.02308312434680694\ \(0\)\
\-\ history\\:\\ 0\\.02220551665516321\ \(0\)\
\-\ at\\:\\ 0\\.021952968277072195\ \(0\)\
\-\ year\\:\\ 0\\.017911691421549098\ \(0\)\
